

WEBVTT

00:00:00.000 -> 00:00:03.384 Support for Yale Cancer Answers comes

NOTE Confidence: 0.83079993724823

00:00:03.384 -> 00:00:05.640 from AstraZeneca, a pharmaceutical

NOTE Confidence: 0.83079993724823

00:00:05.720 -> 00:00:08.975 business that is pushing the boundaries of

NOTE Confidence: 0.83079993724823

00:00:08.975 -> 00:00:12.050 science to deliver new cancer medicines.

NOTE Confidence: 0.83079993724823

00:00:12.050 -> 00:00:15.818 More information at astrazeneca-us.com.

NOTE Confidence: 0.83079993724823

00:00:15.820 -> 00:00:18.034 Welcome to Yale Cancer Answers with

NOTE Confidence: 0.83079993724823

00:00:18.034 -> 00:00:20.459 your host doctor Anees Chagpar.

NOTE Confidence: 0.83079993724823

00:00:20.460 -> 00:00:22.365 Yale Cancer Answers features the

NOTE Confidence: 0.83079993724823

00:00:22.365 -> 00:00:24.708 latest information on cancer care by

NOTE Confidence: 0.83079993724823

00:00:24.708 -> 00:00:26.208 welcoming oncologists and specialists

NOTE Confidence: 0.83079993724823

00:00:26.208 -> 00:00:28.726 who are on the forefront of the

NOTE Confidence: 0.83079993724823

00:00:28.726 -> 00:00:30.460 battle to fight cancer. This week

NOTE Confidence: 0.83079993724823

00:00:30.460 -> 00:00:32.260 it's a conversation about gastroesophageal

NOTE Confidence: 0.83079993724823

00:00:32.260 -> 00:00:34.380 cancer with Doctor Jill Lacy.

NOTE Confidence: 0.83079993724823

00:00:34.380 -> 00:00:37.201 Doctor Lacy is a professor of medicine

NOTE Confidence: 0.83079993724823

00:00:37.201 -> 00:00:39.908 and medical oncology at the Yale School
NOTE Confidence: 0.83079993724823

00:00:39.908 -> 00:00:42.521 of Medicine where Doctor Chagpar is
NOTE Confidence: 0.83079993724823

00:00:42.521 -> 00:00:44.990 a professor of surgical oncology.
NOTE Confidence: 0.825379490852356

00:00:44.990 -> 00:00:48.007 Jill, we don't often talk
NOTE Confidence: 0.825379490852356

00:00:48.007 -> 00:00:50.329 about gastroesophageal cancers much.
NOTE Confidence: 0.825379490852356

00:00:50.330 -> 00:00:53.890 Tell us a little bit more about them.
NOTE Confidence: 0.825379490852356

00:00:53.890 -> 00:00:55.670 How common are they?
NOTE Confidence: 0.825379490852356

00:00:55.670 -> 00:00:57.450 Who do they affect?
NOTE Confidence: 0.825379490852356

00:00:57.450 -> 00:00:59.230 What do they encompass?
NOTE Confidence: 0.825379490852356

00:00:59.230 -> 00:01:02.751 It is somewhat of a heterogeneous group of cancers
NOTE Confidence: 0.825379490852356

00:01:02.751 -> 00:01:05.937 and I will elaborate on that as we go along.
NOTE Confidence: 0.825379490852356

00:01:05.940 -> 00:01:08.868 And it is not a
NOTE Confidence: 0.825379490852356

00:01:08.868 -> 00:01:10.820 common group of cancers
NOTE Confidence: 0.825379490852356

00:01:10.820 -> 00:01:12.768 certainly, compared to, say,
NOTE Confidence: 0.825379490852356

00:01:12.768 -> 00:01:15.203 breast cancer or lung cancer.
NOTE Confidence: 0.825379490852356

00:01:15.210 -> 00:01:17.946 So if you combine esophagus and

NOTE Confidence: 0.825379490852356
00:01:17.946 -> 00:01:21.070 gastric cancer in the United States,
NOTE Confidence: 0.825379490852356
00:01:21.070 -> 00:01:23.998 there's about 46,000 cases a year,
NOTE Confidence: 0.825379490852356
00:01:24.000 -> 00:01:25.464 about 27,000 deaths.
NOTE Confidence: 0.825379490852356
00:01:25.464 -> 00:01:28.880 So it is quite a lethal cancer.
NOTE Confidence: 0.825379490852356
00:01:28.880 -> 00:01:30.341 And by contrast,
NOTE Confidence: 0.825379490852356
00:01:30.341 -> 00:01:32.776 lung cancer over 200,000 cases.
NOTE Confidence: 0.825379490852356
00:01:32.780 -> 00:01:33.828 Breast cancer,
NOTE Confidence: 0.825379490852356
00:01:33.828 -> 00:01:36.448 I believe over 270,000 cases.
NOTE Confidence: 0.825379490852356
00:01:36.450 -> 00:01:37.290 But interestingly,
NOTE Confidence: 0.825379490852356
00:01:37.290 -> 00:01:39.810 the death rate as I indicated,
NOTE Confidence: 0.825379490852356
00:01:39.810 -> 00:01:41.490 still is quite high.
NOTE Confidence: 0.825379490852356
00:01:41.490 -> 00:01:44.470 You compare this, say with breast cancer,
NOTE Confidence: 0.825379490852356
00:01:44.470 -> 00:01:47.536 where I believe we're down to in
NOTE Confidence: 0.825379490852356
00:01:47.536 -> 00:01:50.308 the range of 40,000 deaths per year.
NOTE Confidence: 0.825379490852356
00:01:50.310 -> 00:01:53.670 So even though it's not a common cancer,
NOTE Confidence: 0.825379490852356

00:01:53.670 -> 00:01:55.932 it is still a significant problem
NOTE Confidence: 0.825379490852356

00:01:55.932 -> 00:01:58.290 in terms of its lethality.
00:02:00.810 -> 00:02:02.486 What's interesting about these
NOTE Confidence: 0.825379490852356

00:02:02.486 -> 00:02:04.581 cancers is that there's quite
NOTE Confidence: 0.825379490852356

00:02:04.581 -> 00:02:06.967 a bit of geographic variation in incidence
NOTE Confidence: 0.825379490852356

00:02:06.970 -> 00:02:09.105 and gastric cancer actually
NOTE Confidence: 0.825379490852356

00:02:09.105 -> 00:02:11.797 is quite common worldwide and a
NOTE Confidence: 0.825379490852356

00:02:11.797 -> 00:02:13.749 significant public health problem.
NOTE Confidence: 0.825379490852356

00:02:13.750 -> 00:02:16.318 It's actually the third leading cause
NOTE Confidence: 0.825379490852356

00:02:16.318 -> 00:02:18.720 of cancer related deaths globally.
NOTE Confidence: 0.825379490852356

00:02:18.720 -> 00:02:21.884 Over 1,000,000 cases and over 800,000 deaths.
NOTE Confidence: 0.825379490852356

00:02:21.890 -> 00:02:24.596 So it does remain, I think,
NOTE Confidence: 0.825379490852356

00:02:24.600 -> 00:02:27.210 a huge issue globally and still
NOTE Confidence: 0.825379490852356

00:02:27.210 -> 00:02:29.570 problematic in the United States.
NOTE Confidence: 0.836929976940155

00:02:30.570 -> 00:02:32.620 And on top of that,
NOTE Confidence: 0.836929976940155

00:02:32.620 -> 00:02:34.670 gastroesophageal cancers not only are
NOTE Confidence: 0.836929976940155

00:02:34.670 -> 00:02:37.519 gastric cancers or cancers of the stomach,
NOTE Confidence: 0.836929976940155

00:02:37.520 -> 00:02:39.570 but also of the esophagus.
NOTE Confidence: 0.836929976940155

00:02:39.570 -> 00:02:42.554 But the esophagus is a long tube that
NOTE Confidence: 0.836929976940155

00:02:42.554 -> 00:02:45.488 goes all the way from essentially your
NOTE Confidence: 0.836929976940155

00:02:45.488 -> 00:02:48.978 mouth all the way down to your stomach.
NOTE Confidence: 0.836929976940155

00:02:48.980 -> 00:02:51.428 So talk a little bit about
NOTE Confidence: 0.836929976940155

00:02:51.428 -> 00:02:52.652 whether those cancers,
NOTE Confidence: 0.836929976940155

00:02:52.660 -> 00:02:54.495 the cancers of the esophagus
NOTE Confidence: 0.836929976940155

00:02:54.495 -> 00:02:56.886 and the cancers of the stomach
NOTE Confidence: 0.836929976940155

00:02:56.886 -> 00:02:58.790 are similar or different,
NOTE Confidence: 0.836929976940155

00:02:58.790 -> 00:03:00.835 and whether there are different
NOTE Confidence: 0.836929976940155

00:03:00.835 -> 00:03:02.880 types of cancers even within that.
NOTE Confidence: 0.85228789349397

00:03:02.880 -> 00:03:06.240 Sure, so we often divide these
NOTE Confidence: 0.85228789349397

00:03:06.240 -> 00:03:09.229 cancers into two anatomic groups.
NOTE Confidence: 0.85228789349397

00:03:09.230 -> 00:03:12.380 Esophagus cancer, as you alluded to,
NOTE Confidence: 0.85228789349397

00:03:12.380 -> 00:03:16.588 and gastric, or what we call stomach cancer.

NOTE Confidence: 0.85228789349397
00:03:16.590 -> 00:03:20.078 And esophageal cancer we now know really
NOTE Confidence: 0.85228789349397
00:03:20.078 -> 00:03:23.210 is comprised of two very distinct types,
NOTE Confidence: 0.85228789349397
00:03:23.210 -> 00:03:24.970 really essentially different diseases.
00:03:26.290 -> 00:03:29.118 One type is called squamous cell cancer
NOTE Confidence: 0.85228789349397
00:03:29.118 -> 00:03:32.629 an under the microscope and in terms of
NOTE Confidence: 0.85228789349397
00:03:32.629 -> 00:03:35.550 its molecular biology and risk factors,
NOTE Confidence: 0.85228789349397
00:03:35.550 -> 00:03:38.714 it's actually quite similar to cancers of
NOTE Confidence: 0.85228789349397
00:03:38.714 -> 00:03:42.167 the throat and the head and neck region.
NOTE Confidence: 0.85228789349397
00:03:42.170 -> 00:03:44.828 The risk factor there is tobacco
NOTE Confidence: 0.85228789349397
00:03:44.828 -> 00:03:46.600 and alcohol in poverty.
NOTE Confidence: 0.85228789349397
00:03:46.600 -> 00:03:47.382 And Interestingly,
NOTE Confidence: 0.85228789349397
00:03:47.382 -> 00:03:49.337 the incidence of squamous cell
NOTE Confidence: 0.85228789349397
00:03:49.337 -> 00:03:51.573 carcinoma of the esophagus has
NOTE Confidence: 0.85228789349397
00:03:51.573 -> 00:03:53.067 really dropped dramatically,
NOTE Confidence: 0.85228789349397
00:03:53.070 -> 00:03:55.220 particularly in the Western world,
NOTE Confidence: 0.85228789349397
00:03:55.220 -> 00:03:57.380 so that's the good news.

NOTE Confidence: 0.85228789349397

00:03:57.380 -> 00:03:59.530 The other type of esophagus

NOTE Confidence: 0.85228789349397

00:03:59.530 -> 00:04:01.250 cancer is called adenocarcinoma,

NOTE Confidence: 0.85228789349397

00:04:01.250 -> 00:04:03.818 and then actually arises at the

NOTE Confidence: 0.85228789349397

00:04:03.818 -> 00:04:06.463 bottom of the esophagus where it

NOTE Confidence: 0.85228789349397

00:04:06.463 -> 00:04:08.578 connects in with the stomach,

NOTE Confidence: 0.85228789349397

00:04:08.580 -> 00:04:10.304 often referred to as

NOTE Confidence: 0.85228789349397

00:04:10.304 -> 00:04:11.597 gastroesophageal junction cancer,

NOTE Confidence: 0.85228789349397

00:04:11.600 -> 00:04:14.808 and that looks much more like a typical

NOTE Confidence: 0.85228789349397

00:04:14.808 -> 00:04:17.249 gastric cancer under the microscope.

NOTE Confidence: 0.85228789349397

00:04:17.250 -> 00:04:19.966 And actually is much more similar to

NOTE Confidence: 0.85228789349397

00:04:19.966 -> 00:04:22.678 gastric cancer than it is to squamous

NOTE Confidence: 0.85228789349397

00:04:22.678 -> 00:04:24.523 cell cancers of the esophagus.

NOTE Confidence: 0.85228789349397

00:04:24.530 -> 00:04:25.676 And they are.

NOTE Confidence: 0.85228789349397

00:04:25.676 -> 00:04:27.586 They have different risk factors,

NOTE Confidence: 0.85228789349397

00:04:27.590 -> 00:04:28.214 so I,

NOTE Confidence: 0.85228789349397

00:04:28.214 -> 00:04:30.710 for I alluded to the risk factors for
NOTE Confidence: 0.85228789349397

00:04:30.785 -> 00:04:34.033 squamous cell of these saw fickas it's
NOTE Confidence: 0.85228789349397

00:04:34.033 -> 00:04:35.860 predominantly tobacco and alcohol
NOTE Confidence: 0.85228789349397

00:04:35.860 -> 00:04:38.700 as we see with head and neck cancer.
NOTE Confidence: 0.85228789349397

00:04:38.700 -> 00:04:41.736 For the adenocarcinomas of the esophagus
NOTE Confidence: 0.85228789349397

00:04:41.736 -> 00:04:45.950 that arise at the bottom of the esophagus.
NOTE Confidence: 0.85228789349397

00:04:45.950 -> 00:04:47.974 What's interesting about that
NOTE Confidence: 0.85228789349397

00:04:47.974 -> 00:04:51.010 is that there actually has been
NOTE Confidence: 0.85228789349397

00:04:51.099 -> 00:04:54.135 quite a dramatic increase in the
NOTE Confidence: 0.85228789349397

00:04:54.135 -> 00:04:56.830 incidence of this particular entity.
NOTE Confidence: 0.85228789349397

00:04:56.830 -> 00:04:58.384 Gastroesophageal junction adenocarcinoma,
NOTE Confidence: 0.85228789349397

00:04:58.384 -> 00:05:00.456 particularly in Caucasian males,
NOTE Confidence: 0.85228789349397

00:05:00.460 -> 00:05:03.838 a great male predominant we don't
NOTE Confidence: 0.85228789349397

00:05:03.838 -> 00:05:06.632 fully understand that increase some
NOTE Confidence: 0.85228789349397

00:05:06.632 -> 00:05:09.789 of the risk factors that are linked.
NOTE Confidence: 0.85228789349397

00:05:09.790 -> 00:05:13.085 Two adenocarcinoma of the esophagus

NOTE Confidence: 0.85228789349397

00:05:13.085 -> 00:05:16.380 are high BMI or obesity.

NOTE Confidence: 0.85228789349397

00:05:16.380 -> 00:05:18.920 Possibly Dyett gastro oesophageal

NOTE Confidence: 0.85228789349397

00:05:18.920 -> 00:05:22.095 reflux disease is certainly risk

NOTE Confidence: 0.85228789349397

00:05:22.095 -> 00:05:24.039 factor in some cases,

NOTE Confidence: 0.85228789349397

00:05:24.040 -> 00:05:27.302 but smoking and alcohol do not seem

NOTE Confidence: 0.85228789349397

00:05:27.302 -> 00:05:32.376 to play a predominant role in risk

NOTE Confidence: 0.85228789349397

00:05:32.376 -> 00:05:35.948 factor the gastroesophageal adenocarcinomas.

NOTE Confidence: 0.85228789349397

00:05:35.950 -> 00:05:39.558 Then you get into the stomach an we're

NOTE Confidence: 0.85228789349397

00:05:39.558 -> 00:05:42.548 talking about classic gastric cancer.

NOTE Confidence: 0.85228789349397

00:05:42.550 -> 00:05:45.940 And there what's very interesting is

NOTE Confidence: 0.85228789349397

00:05:45.940 -> 00:05:50.320 that there's been a progressive decline.

NOTE Confidence: 0.85228789349397

00:05:50.320 -> 00:05:53.208 Across the globe and in the United States.

NOTE Confidence: 0.85228789349397

00:05:53.210 -> 00:05:55.082 In the incidence of gastric cancer

NOTE Confidence: 0.85228789349397

00:05:55.082 -> 00:05:57.608 as it was the number one cause

NOTE Confidence: 0.85228789349397

00:05:57.608 -> 00:05:59.623 of cancer related deaths globally

NOTE Confidence: 0.85228789349397

00:05:59.623 -> 00:06:01.149 until about the 1980s,
NOTE Confidence: 0.85228789349397

00:06:01.150 -> 00:06:03.572 when it was surpassed by lung cancer
NOTE Confidence: 0.85228789349397

00:06:03.572 -> 00:06:06.160 and there are a lot of interesting
NOTE Confidence: 0.85228789349397

00:06:06.160 -> 00:06:08.005 theories about why that is.
NOTE Confidence: 0.85228789349397

00:06:08.010 -> 00:06:11.601 And we do know that there are some risk
NOTE Confidence: 0.85228789349397

00:06:11.601 -> 00:06:14.640 factors for stomach or gastric cancer,
NOTE Confidence: 0.85228789349397

00:06:14.640 -> 00:06:16.850 and these include some environmental
NOTE Confidence: 0.85228789349397

00:06:16.850 -> 00:06:18.618 and lifestyle risk factors.
NOTE Confidence: 0.85228789349397

00:06:18.620 -> 00:06:21.616 One of the most prominent is a
NOTE Confidence: 0.85228789349397

00:06:21.616 -> 00:06:23.480 bacteria called *Helicobacter pylori*,
NOTE Confidence: 0.85228789349397

00:06:23.480 -> 00:06:26.240 which is quite prevalent and some
NOTE Confidence: 0.85228789349397

00:06:26.240 -> 00:06:29.021 strains of that bacteria are cancer
NOTE Confidence: 0.85228789349397

00:06:29.021 -> 00:06:32.017 causing and do increase the risk of
NOTE Confidence: 0.85228789349397

00:06:32.017 -> 00:06:35.052 gastric cancer through been a lot of
NOTE Confidence: 0.85228789349397

00:06:35.052 -> 00:06:37.642 studies over the decades about diet.
NOTE Confidence: 0.85228789349397

00:06:37.642 -> 00:06:39.897 So it does seem that.

NOTE Confidence: 0.85228789349397
00:06:39.900 -> 00:06:42.456 Salt preserved and smoked foods increase
NOTE Confidence: 0.85228789349397
00:06:42.456 -> 00:06:45.856 the risk as well as dietze that are
NOTE Confidence: 0.85228789349397
00:06:45.856 -> 00:06:48.280 low in fresh fruits and vegetables.
NOTE Confidence: 0.85228789349397
00:06:48.280 -> 00:06:50.536 Modest risks risk factors would be
NOTE Confidence: 0.85228789349397
00:06:50.536 -> 00:06:52.598 smoking and obesity and probably
NOTE Confidence: 0.85228789349397
00:06:52.598 -> 00:06:54.566 lower social economic status.
NOTE Confidence: 0.826479136943817
00:06:54.570 -> 00:06:57.496 So there are a lot of differences,
NOTE Confidence: 0.826479136943817
00:06:57.500 -> 00:06:59.912 not only anatomically and in terms
NOTE Confidence: 0.826479136943817
00:06:59.912 -> 00:07:02.459 of the pathology under the microscope
NOTE Confidence: 0.826479136943817
00:07:02.459 -> 00:07:05.040 but also risk factors, and it's
NOTE Confidence: 0.826479136943817
00:07:05.040 -> 00:07:07.250 interesting deals that you mentioned
NOTE Confidence: 0.826479136943817
00:07:07.250 -> 00:07:09.460 that the oesophageal cancer rate
NOTE Confidence: 0.826479136943817
00:07:09.533 -> 00:07:11.328 and the gastric cancer rate.
NOTE Confidence: 0.826479136943817
00:07:11.330 -> 00:07:14.540 Both seems to have dropped,
NOTE Confidence: 0.826479136943817
00:07:14.540 -> 00:07:16.466 but gastroesophageal cancers,
NOTE Confidence: 0.826479136943817

00:07:16.466 -> 00:07:20.960 those cancers that occur at that junction,
NOTE Confidence: 0.826479136943817

00:07:20.960 -> 00:07:23.320 the add node cancers.
NOTE Confidence: 0.826479136943817

00:07:23.320 -> 00:07:25.090 Have increased Ann.
NOTE Confidence: 0.826479136943817

00:07:25.090 -> 00:07:28.415 You mentioned that we we don't know
NOTE Confidence: 0.826479136943817

00:07:28.415 -> 00:07:31.280 why exactly those have increased,
NOTE Confidence: 0.826479136943817

00:07:31.280 -> 00:07:34.220 but do we have any insight into
NOTE Confidence: 0.826479136943817

00:07:34.220 -> 00:07:38.017 what played a role in decreasing the
NOTE Confidence: 0.826479136943817

00:07:38.017 -> 00:07:41.072 incidence of oesophageal cancers and
NOTE Confidence: 0.819761395454407

00:07:41.080 -> 00:07:42.649 of gastric cancers?
NOTE Confidence: 0.819761395454407

00:07:42.649 -> 00:07:45.264 So for squamous cell carcinoma
NOTE Confidence: 0.819761395454407

00:07:45.264 -> 00:07:48.399 of the esophagus it is related
NOTE Confidence: 0.819761395454407

00:07:48.399 -> 00:07:50.894 to a decrease in smoking.
NOTE Confidence: 0.819761395454407

00:07:50.900 -> 00:07:52.920 And improvements in social
NOTE Confidence: 0.819761395454407

00:07:52.920 -> 00:07:54.940 economic status and nutrition.
NOTE Confidence: 0.819761395454407

00:07:54.940 -> 00:07:58.484 Those seem to be quite linked to squamous
NOTE Confidence: 0.819761395454407

00:07:58.484 -> 00:08:02.520 of the esophagus and for gastric cancer,

NOTE Confidence: 0.819761395454407
00:08:02.520 -> 00:08:06.342 we do think that it does relate
NOTE Confidence: 0.819761395454407
00:08:06.342 -> 00:08:08.579 to decreasing incidence of
NOTE Confidence: 0.819761395454407
00:08:08.580 -> 00:08:11.100 H. Pylori colonization or infection related,
NOTE Confidence: 0.819761395454407
00:08:11.100 -> 00:08:12.615 likely due to refrigeration
NOTE Confidence: 0.819761395454407
00:08:12.615 -> 00:08:15.645 over the last century or so.
NOTE Confidence: 0.819761395454407
00:08:15.650 -> 00:08:19.906 So in areas of the world that are
NOTE Confidence: 0.819761395454407
00:08:19.906 -> 00:08:21.729 underdeveloped we see
NOTE Confidence: 0.819761395454407
00:08:21.730 -> 00:08:24.946 a drop in the incidence of gastric cancer,
NOTE Confidence: 0.819761395454407
00:08:24.950 -> 00:08:26.960 so that's the prevailing theory.
00:08:27.360 -> 00:08:29.370 But you know, it's interesting
NOTE Confidence: 0.870746791362762
00:08:29.370 -> 00:08:30.978 that despite these advances,
NOTE Confidence: 0.870746791362762
00:08:30.980 -> 00:08:34.188 and certainly there's a long way to go,
NOTE Confidence: 0.870746791362762
00:08:34.190 -> 00:08:36.596 this is still, as you mentioned,
NOTE Confidence: 0.870746791362762
00:08:36.600 -> 00:08:38.376 a fairly lethal cancer
NOTE Confidence: 0.870746791362762
00:08:38.376 -> 00:08:40.596 when we think about gastroesophageal
NOTE Confidence: 0.870746791362762
00:08:40.596 -> 00:08:41.828 cancers as a whole,

NOTE Confidence: 0.870746791362762

00:08:41.830 -> 00:08:44.170 is that because they tend to

NOTE Confidence: 0.870746791362762

00:08:44.170 -> 00:08:46.650 present at late stages in general?

NOTE Confidence: 0.874626100063324

00:08:47.260 -> 00:08:51.013 I think it's a combination of factors.

NOTE Confidence: 0.874626100063324

00:08:51.020 -> 00:08:53.946 Yes they are lethal cancers,

NOTE Confidence: 0.874626100063324

00:08:53.950 -> 00:08:56.356 and that's why even though they're

NOTE Confidence: 0.874626100063324

00:08:56.356 -> 00:08:58.550 not so common in the United States,

NOTE Confidence: 0.874626100063324

00:08:58.550 -> 00:09:00.310 they're still very problematic.

NOTE Confidence: 0.874626100063324

00:09:00.310 -> 00:09:03.411 So the five year cure rate for

NOTE Confidence: 0.874626100063324

00:09:03.411 -> 00:09:06.064 esophageal cancer was only about 20%.

NOTE Confidence: 0.874626100063324

00:09:06.070 -> 00:09:09.406 It's a little bit higher for gastric cancer,

NOTE Confidence: 0.874626100063324

00:09:09.410 -> 00:09:12.522 about 30%, and I think the reasons for

NOTE Confidence: 0.874626100063324

00:09:12.522 -> 00:09:15.709 this are multi factorial if you will.

NOTE Confidence: 0.874626100063324

00:09:15.710 -> 00:09:19.634 In some cases, due to a delay in diagnosis,

NOTE Confidence: 0.874626100063324

00:09:19.640 -> 00:09:23.136 but I don't think that's the major reason.

NOTE Confidence: 0.874626100063324

00:09:23.140 -> 00:09:26.623 I think it has much to do with the

NOTE Confidence: 0.874626100063324

00:09:26.623 -> 00:09:29.260 inherent biology of these tumors.

NOTE Confidence: 0.874626100063324

00:09:29.260 -> 00:09:31.004 A propensity to disseminate

NOTE Confidence: 0.874626100063324

00:09:31.004 -> 00:09:32.748 or spread early on,

NOTE Confidence: 0.874626100063324

00:09:32.750 -> 00:09:35.186 and then the need for better

NOTE Confidence: 0.874626100063324

00:09:35.186 -> 00:09:37.370 and more effective therapies to

NOTE Confidence: 0.874626100063324

00:09:37.370 -> 00:09:39.306 deal with disseminated disease.

NOTE Confidence: 0.874626100063324

00:09:39.310 -> 00:09:42.635 I would add that in contrast to

NOTE Confidence: 0.874626100063324

00:09:42.635 -> 00:09:45.580 the common cancers such as breast,

NOTE Confidence: 0.874626100063324

00:09:45.580 -> 00:09:46.918 colorectal, lung, and cervical

NOTE Confidence: 0.874626100063324

00:09:46.918 -> 00:09:49.148 there is no widespread screening

NOTE Confidence: 0.874626100063324

00:09:49.148 -> 00:09:50.630 for these cancers,

NOTE Confidence: 0.874626100063324

00:09:50.630 -> 00:09:53.378 at least in the Western world.

00:09:54.972 -> 00:09:56.962 But it is a little bit different in Asia

NOTE Confidence: 0.874626100063324

00:09:56.962 -> 00:09:59.348 and therefore early detection

NOTE Confidence: 0.874626100063324

00:09:59.350 -> 00:10:02.170 is less likely to happen with

NOTE Confidence: 0.874626100063324

00:10:02.170 -> 00:10:04.400 these cancers as opposed to

00:10:04.859 -> 00:10:05.777 breast cancer,

NOTE Confidence: 0.874626100063324
00:10:05.777 -> 00:10:08.990 so that certainly would be a contributing
NOTE Confidence: 0.830530166625977
00:10:08.990 -> 00:10:12.343 factor.
NOTE Confidence: 0.830530166625977
00:10:12.343 -> 00:10:14.499 Talk a little bit about the differences in screening
in Asia.
00:10:15.964 -> 00:10:18.160 How do people in Asia get screened for
NOTE Confidence: 0.830530166625977
00:10:18.245 -> 00:10:20.475 esophageal cancers and why
NOTE Confidence: 0.830530166625977
00:10:20.475 -> 00:10:24.218 hasn't that been adopted in the US?
NOTE Confidence: 0.830530166625977
00:10:24.220 -> 00:10:26.973 Usually we find screening to be more
NOTE Confidence: 0.830530166625977
00:10:26.973 -> 00:10:29.332 prevalent in the Western world than
NOTE Confidence: 0.830530166625977
00:10:29.332 -> 00:10:31.690 we do in less developed countries.
NOTE Confidence: 0.869833290576935
00:10:32.460 -> 00:10:34.570 In terms of
NOTE Confidence: 0.869833290576935
00:10:34.570 -> 00:10:37.280 screening in Asia for gastric cancer
NOTE Confidence: 0.869833290576935
00:10:37.280 -> 00:10:39.088 they do pretty sophisticated
NOTE Confidence: 0.869833290576935
00:10:39.088 -> 00:10:41.800 radiographic studies to look at
NOTE Confidence: 0.869833290576935
00:10:41.880 -> 00:10:43.926 the surface of the stomach to
NOTE Confidence: 0.869833290576935
00:10:43.926 -> 00:10:46.480 see if there are irregularities,
NOTE Confidence: 0.869833290576935

00:10:46.480 -> 00:10:49.080 and then for esophagus cancer
NOTE Confidence: 0.869833290576935

00:10:49.080 -> 00:10:51.160 screening modalities is to have
NOTE Confidence: 0.869833290576935

00:10:51.160 -> 00:10:53.632 patients swallow a balloon and sort
NOTE Confidence: 0.869833290576935

00:10:53.632 -> 00:10:56.385 of pull it up through the esophagus
NOTE Confidence: 0.869833290576935

00:10:56.385 -> 00:10:58.809 and you pull off abnormal cells
NOTE Confidence: 0.869833290576935

00:10:58.809 -> 00:11:01.400 in the lining of the esophagus.
NOTE Confidence: 0.869833290576935

00:11:01.400 -> 00:11:04.070 And those are two screening modalities.
NOTE Confidence: 0.869833290576935

00:11:04.070 -> 00:11:08.182 That can be applied widely in the United
NOTE Confidence: 0.869833290576935

00:11:08.182 -> 00:11:11.650 States because it is an uncommon cancer.
NOTE Confidence: 0.869833290576935

00:11:11.650 -> 00:11:15.154 I think there's just not been a lot
NOTE Confidence: 0.869833290576935

00:11:15.154 -> 00:11:18.719 of focus on widespread screening
NOTE Confidence: 0.850119761058262

00:11:18.720 -> 00:11:20.226 for these cancers.
NOTE Confidence: 0.850119761058262

00:11:20.226 -> 00:11:23.238 So you mentioned that these cancers
NOTE Confidence: 0.850119761058262

00:11:23.238 -> 00:11:25.959 tend to, because of their biology,
NOTE Confidence: 0.850119761058262

00:11:25.960 -> 00:11:27.836 be more advanced
NOTE Confidence: 0.850119761058262

00:11:27.836 -> 00:11:30.181 at the time of presentation

NOTE Confidence: 0.850119761058262
00:11:30.181 -> 00:11:33.667 and more rapidly get to a more
NOTE Confidence: 0.850119761058262
00:11:33.667 -> 00:11:35.615 advanced or metastatic stage,
NOTE Confidence: 0.850119761058262
00:11:35.620 -> 00:11:37.755 what proportion of
NOTE Confidence: 0.850119761058262
00:11:37.755 -> 00:11:39.463 these patients present with
NOTE Confidence: 0.850119761058262
00:11:39.463 -> 00:11:41.378 advanced or metastatic disease,
NOTE Confidence: 0.850119761058262
00:11:41.380 -> 00:11:43.590 out of all
NOTE Confidence: 0.850119761058262
00:11:43.590 -> 00:11:46.248 the gastroesophageal cancers that you see?
NOTE Confidence: 0.844509780406952
00:11:46.780 -> 00:11:50.188 Still the majority of the
NOTE Confidence: 0.844509780406952
00:11:50.188 -> 00:11:53.406 patients are presenting with non
NOTE Confidence: 0.844509780406952
00:11:53.406 -> 00:11:56.758 disseminated or nonmetastatic disease,
NOTE Confidence: 0.844509780406952
00:11:56.760 -> 00:12:00.080 so that's the good news.
NOTE Confidence: 0.844509780406952
00:12:00.080 -> 00:12:03.104 But despite that, again
NOTE Confidence: 0.844509780406952
00:12:03.104 -> 00:12:04.616 oftentimes particularly
NOTE Confidence: 0.844509780406952
00:12:04.620 -> 00:12:06.705 with the more advanced but
NOTE Confidence: 0.844509780406952
00:12:06.705 -> 00:12:07.956 still nonmetastatic cases,
NOTE Confidence: 0.844509780406952

00:12:07.960 -> 00:12:11.288 there is what we call a cult dissemination,

NOTE Confidence: 0.844509780406952

00:12:11.290 -> 00:12:14.378 and that is where we look to additional

NOTE Confidence: 0.844509780406952

00:12:14.378 -> 00:12:16.129 therapies such as chemotherapy

NOTE Confidence: 0.844509780406952

00:12:16.129 -> 00:12:18.379 to try to increase security.

NOTE Confidence: 0.844509780406952

00:12:18.380 -> 00:12:20.435 You know, it's something that

NOTE Confidence: 0.844509780406952

00:12:20.435 -> 00:12:22.490 we've been doing for several

NOTE Confidence: 0.844509780406952

00:12:22.566 -> 00:12:25.050 decades in the breast cancer world,

NOTE Confidence: 0.844509780406952

00:12:25.050 -> 00:12:27.135 and certainly has a role

NOTE Confidence: 0.844509780406952

00:12:27.135 -> 00:12:29.220 in these cancers as well.

NOTE Confidence: 0.844509780406952

00:12:29.220 -> 00:12:30.990 Even in those patients who

NOTE Confidence: 0.844509780406952

00:12:30.990 -> 00:12:32.760 appear to have localized and

NOTE Confidence: 0.844509780406952

00:12:32.833 -> 00:12:34.639 potentially curable disease.

NOTE Confidence: 0.859931170940399

00:12:34.790 -> 00:12:38.130 And I want to kind of get

NOTE Confidence: 0.859931170940399

00:12:38.219 -> 00:12:41.558 into how exactly we treat patients,

NOTE Confidence: 0.859931170940399

00:12:41.560 -> 00:12:43.942 and so with those patients with

NOTE Confidence: 0.859931170940399

00:12:43.942 -> 00:12:45.931 localized disease, can we treat

NOTE Confidence: 0.859931170940399
00:12:45.931 -> 00:12:47.916 these patients for curative intent?
NOTE Confidence: 0.859931170940399
00:12:47.920 -> 00:12:50.308 And how do we do that?
NOTE Confidence: 0.842579483985901
00:12:50.940 -> 00:12:53.415 Absolutely, patients who
NOTE Confidence: 0.842579483985901
00:12:53.415 -> 00:12:55.395 present with nonmetastatic disease,
NOTE Confidence: 0.842579483985901
00:12:55.400 -> 00:12:57.840 so no evidence of dissemination
NOTE Confidence: 0.842579483985901
00:12:57.840 -> 00:13:00.840 to other sites in the body,
NOTE Confidence: 0.842579483985901
00:13:00.840 -> 00:13:02.820 and that we determined
NOTE Confidence: 0.842579483985901
00:13:02.820 -> 00:13:04.800 simply by getting imaging,
NOTE Confidence: 0.842579483985901
00:13:04.800 -> 00:13:07.656 usually a CAT scan or in
NOTE Confidence: 0.842579483985901
00:13:07.656 -> 00:13:10.250 some cases a PET scan.
NOTE Confidence: 0.842579483985901
00:13:10.250 -> 00:13:13.906 And for those patients there is a path
NOTE Confidence: 0.842579483985901
00:13:13.906 -> 00:13:17.666 to cure for many of those patients,
NOTE Confidence: 0.842579483985901
00:13:17.670 -> 00:13:19.662 and that often involves
NOTE Confidence: 0.842579483985901
00:13:19.662 -> 00:13:21.654 surgery as the centerpiece
NOTE Confidence: 0.842579483985901
00:13:21.660 -> 00:13:24.945 of the cure and then in many cases where
NOTE Confidence: 0.842579483985901

00:13:24.945 -> 00:13:28.128 the disease is more locally advanced,
NOTE Confidence: 0.842579483985901

00:13:28.130 -> 00:13:30.220 we will need adjunctive therapies
NOTE Confidence: 0.842579483985901

00:13:30.220 -> 00:13:32.310 in addition to surgery to
NOTE Confidence: 0.842579483985901

00:13:32.389 -> 00:13:34.589 further increase the cure rate.
NOTE Confidence: 0.842579483985901

00:13:34.590 -> 00:13:36.745 And that's true both for
NOTE Confidence: 0.842579483985901

00:13:36.745 -> 00:13:38.900 esophagus cancer and for gastric
NOTE Confidence: 0.853434478243192

00:13:38.900 -> 00:13:41.996 cancer.
NOTE Confidence: 0.853434478243192

00:13:41.996 -> 00:13:45.619 When the disease has spread or is more advanced,
NOTE Confidence: 0.853434478243192

00:13:45.620 -> 00:13:49.604 I would imagine that therapies can be a
NOTE Confidence: 0.853434478243192

00:13:49.604 -> 00:13:53.900 little bit more challenging or problematic
NOTE Confidence: 0.853434478243192

00:13:53.900 -> 00:13:55.730 but I do understand that
NOTE Confidence: 0.853434478243192

00:13:55.730 -> 00:13:57.775 there are some new advances that
NOTE Confidence: 0.853434478243192

00:13:57.775 -> 00:14:00.043 may help patients who have more
NOTE Confidence: 0.853434478243192

00:14:00.043 -> 00:14:02.129 advanced or metastatic disease.
NOTE Confidence: 0.853434478243192

00:14:02.130 -> 00:14:05.487 So I want to get into all of that,
NOTE Confidence: 0.853434478243192

00:14:05.490 -> 00:14:08.234 but first we need to take a short

NOTE Confidence: 0.853434478243192
00:14:08.234 -> 00:14:10.359 break for a medical minute,
NOTE Confidence: 0.853434478243192
00:14:10.360 -> 00:14:12.929 so please stay tuned to learn more
NOTE Confidence: 0.853434478243192
00:14:12.929 -> 00:14:14.470 about gastroesophageal cancer
NOTE Confidence: 0.870499312877655
00:14:14.470 -> 00:14:17.254 with my guest Doctor Jill Lacy.
NOTE Confidence: 0.870499312877655
00:14:17.254 -> 00:14:20.077 Support or Yale Cancer Answers comes from AstraZeneca,
NOTE Confidence: 0.870499312877655
00:14:20.080 -> 00:14:22.005 a science LED biopharmaceutical company
NOTE Confidence: 0.870499312877655
00:14:22.005 -> 00:14:23.930 dedicated to partnering across the
NOTE Confidence: 0.870499312877655
00:14:23.984 -> 00:14:25.829 oncology community to improve outcomes
NOTE Confidence: 0.870499312877655
00:14:25.829 -> 00:14:27.674 across various stages of cancer.
NOTE Confidence: 0.870499312877655
00:14:27.680 -> 00:14:34.151 More at astrazeneca-us.com. This is a
NOTE Confidence: 0.870499312877655
00:14:34.151 -> 00:14:36.186 medical minute about breast cancer,
NOTE Confidence: 0.870499312877655
00:14:36.190 -> 00:14:38.220 the most common cancer in
NOTE Confidence: 0.870499312877655
00:14:38.220 -> 00:14:39.844 women. In Connecticut alone,
NOTE Confidence: 0.870499312877655
00:14:39.850 -> 00:14:41.900 approximately 3000 women will be
NOTE Confidence: 0.870499312877655
00:14:41.900 -> 00:14:44.330 diagnosed with breast cancer this year,

NOTE Confidence: 0.870499312877655
00:14:44.330 -> 00:14:46.360 but thanks to earlier detection,
NOTE Confidence: 0.870499312877655
00:14:46.360 -> 00:14:47.578 non invasive treatments,
NOTE Confidence: 0.870499312877655
00:14:47.578 -> 00:14:48.796 and novel therapies,
NOTE Confidence: 0.870499312877655
00:14:48.800 -> 00:14:51.621 there are more options for patients to
NOTE Confidence: 0.870499312877655
00:14:51.621 -> 00:14:54.089 fight breast cancer then ever before.
NOTE Confidence: 0.870499312877655
00:14:54.090 -> 00:14:56.125 Women should schedule a baseline
NOTE Confidence: 0.870499312877655
00:14:56.125 -> 00:14:58.621 mammogram beginning at age 40 or
NOTE Confidence: 0.870499312877655
00:14:58.621 -> 00:15:00.949 earlier if they have risk factors
NOTE Confidence: 0.870499312877655
00:15:00.949 -> 00:15:02.640 associated with breast cancer.
NOTE Confidence: 0.870499312877655
00:15:02.640 -> 00:15:04.530 Digital breast tomosynthesis or
NOTE Confidence: 0.870499312877655
00:15:04.530 -> 00:15:06.042 3D mammography is transforming
NOTE Confidence: 0.870499312877655
00:15:06.042 -> 00:15:07.938 breast screening by significantly
NOTE Confidence: 0.870499312877655
00:15:07.940 -> 00:15:09.539 reducing unnecessary procedures
NOTE Confidence: 0.870499312877655
00:15:09.539 -> 00:15:12.737 while picking up more cancers and
NOTE Confidence: 0.870499312877655
00:15:12.737 -> 00:15:15.302 eliminating some of the fear
NOTE Confidence: 0.870499312877655

00:15:15.302 -> 00:15:17.257 and anxiety many women experience.

NOTE Confidence: 0.870499312877655

00:15:17.260 -> 00:15:19.124 More information is available

NOTE Confidence: 0.870499312877655

00:15:19.124 -> 00:15:20.056 at yalecancercenter.org.

NOTE Confidence: 0.870499312877655

00:15:20.060 -> 00:15:23.978 You're listening to Connecticut Public Radio.

NOTE Confidence: 0.870499312877655

00:15:23.980 -> 00:15:24.410 Welcome

NOTE Confidence: 0.852033913135529

00:15:24.410 -> 00:15:26.560 back to Yale Cancer Answers.

NOTE Confidence: 0.852033913135529

00:15:26.560 -> 00:15:28.960 This is doctor Anees Chagpar

NOTE Confidence: 0.852033913135529

00:15:28.960 -> 00:15:31.570 and I'm joined tonight by

NOTE Confidence: 0.852033913135529

00:15:31.570 -> 00:15:33.870 my guest doctor Jill Lacy.

NOTE Confidence: 0.852033913135529

00:15:33.870 -> 00:15:36.005 We're talking about gastroesophageal

NOTE Confidence: 0.852033913135529

00:15:36.005 -> 00:15:38.600 cancer and right before the break

NOTE Confidence: 0.852033913135529

00:15:38.600 -> 00:15:40.600 Jill was telling us about

NOTE Confidence: 0.852033913135529

00:15:40.600 -> 00:15:43.330 how this is a rare cancer,

NOTE Confidence: 0.852033913135529

00:15:43.330 -> 00:15:45.238 but one that really is fatal

NOTE Confidence: 0.852033913135529

00:15:45.238 -> 00:15:47.599 for some patients and

NOTE Confidence: 0.852033913135529

00:15:47.599 -> 00:15:49.623 especially difficult or perhaps

NOTE Confidence: 0.852033913135529
00:15:49.623 -> 00:15:52.667 more challenging to treat in the
NOTE Confidence: 0.852033913135529
00:15:52.667 -> 00:15:54.547 advanced and metastatic setting.
NOTE Confidence: 0.852033913135529
00:15:54.550 -> 00:15:57.846 So Jill tell us a little bit more
NOTE Confidence: 0.852033913135529
00:15:57.846 -> 00:16:00.414 about historically the options that
NOTE Confidence: 0.852033913135529
00:16:00.414 -> 00:16:03.738 we've had for advanced metastatic
NOTE Confidence: 0.852033913135529
00:16:03.738 -> 00:16:05.252 gastroesophageal cancers and
NOTE Confidence: 0.852033913135529
00:16:05.252 -> 00:16:07.868 some of the new developments that
NOTE Confidence: 0.852033913135529
00:16:07.868 -> 00:16:10.628 maybe can give patients more hope.
NOTE Confidence: 0.851593136787415
00:16:11.220 -> 00:16:15.385 For most of my career,
NOTE Confidence: 0.851593136787415
00:16:15.390 -> 00:16:17.726 when patients develop
NOTE Confidence: 0.851593136787415
00:16:17.726 -> 00:16:19.478 metastatic or disseminated
NOTE Confidence: 0.851593136787415
00:16:19.478 -> 00:16:21.950 esophageal or gastric cancers,
NOTE Confidence: 0.851593136787415
00:16:21.950 -> 00:16:26.115 we were able to offer some treatments,
NOTE Confidence: 0.851593136787415
00:16:26.120 -> 00:16:29.886 but the prognosis was poor and the
NOTE Confidence: 0.851593136787415
00:16:29.886 -> 00:16:33.549 survival was relatively short and those
NOTE Confidence: 0.851593136787415

00:16:33.549 -> 00:16:36.799 treatments up until relatively recently
NOTE Confidence: 0.851593136787415

00:16:36.799 -> 00:16:40.419 were basically the use of chemotherapy,
NOTE Confidence: 0.851593136787415

00:16:40.420 -> 00:16:42.238 or cytotoxic drugs.
NOTE Confidence: 0.851593136787415

00:16:42.238 -> 00:16:44.056 Traditional chemotherapy drugs.
NOTE Confidence: 0.851593136787415

00:16:44.060 -> 00:16:46.236 And those drugs,
NOTE Confidence: 0.851593136787415

00:16:46.236 -> 00:16:48.412 often provided some palliation
NOTE Confidence: 0.851593136787415

00:16:48.412 -> 00:16:51.080 and mostly prolong survival,
NOTE Confidence: 0.851593136787415

00:16:51.080 -> 00:16:54.005 but it was unusual to
NOTE Confidence: 0.851593136787415

00:16:54.005 -> 00:16:55.760 see long-term survivors,
NOTE Confidence: 0.851593136787415

00:16:55.760 -> 00:17:00.308 and we were not curing patients
NOTE Confidence: 0.851593136787415

00:17:00.308 -> 00:17:02.582 with those treatments.
00:17:03.120 -> 00:17:06.270 What changed more recently?
NOTE Confidence: 0.857162296772003

00:17:07.010 -> 00:17:11.322 There have been some very exciting advances in
NOTE Confidence: 0.857162296772003

00:17:11.322 -> 00:17:14.930 the treatment of metastatic, or disseminated,
NOTE Confidence: 0.857162296772003

00:17:14.930 -> 00:17:17.755 both esophageal and gastric cancers.
NOTE Confidence: 0.857162296772003

00:17:17.760 -> 00:17:21.440 The first advance came about a decade
NOTE Confidence: 0.857162296772003

00:17:21.440 -> 00:17:27.088 ago and this was in the area of gastric
NOTE Confidence: 0.857162296772003

00:17:27.088 -> 00:17:29.071 and gastroesophageal adenocarcinomas.
NOTE Confidence: 0.857162296772003

00:17:29.080 -> 00:17:34.030 And what we had learned was that these are
NOTE Confidence: 0.857162296772003

00:17:34.030 -> 00:17:37.529 heterogeneous from a molecular perspective.
NOTE Confidence: 0.857162296772003

00:17:37.530 -> 00:17:42.176 And about 20 to 30% of these tumors carried
NOTE Confidence: 0.857162296772003

00:17:42.176 -> 00:17:46.180 high levels of a protein called Her 2,
NOTE Confidence: 0.857162296772003

00:17:46.180 -> 00:17:48.982 and we knew that this protein
NOTE Confidence: 0.857162296772003

00:17:48.982 -> 00:17:52.289 also was present in breast cancer.
NOTE Confidence: 0.857162296772003

00:17:54.630 -> 00:17:57.890 And a drug had been developed
NOTE Confidence: 0.857162296772003

00:17:57.890 -> 00:18:00.265 called an antibody that
NOTE Confidence: 0.857162296772003

00:18:00.265 -> 00:18:03.284 targeted her 2 in breast cancer and
NOTE Confidence: 0.857162296772003

00:18:03.284 -> 00:18:05.528 it was extraordinarily effective.
NOTE Confidence: 0.857162296772003

00:18:05.530 -> 00:18:08.120 That drug is trastuzumab, or Herceptin.
NOTE Confidence: 0.857162296772003

00:18:08.120 -> 00:18:09.876 And so it was
NOTE Confidence: 0.857162296772003

00:18:09.876 -> 00:18:12.071 theorized that perhaps
NOTE Confidence: 0.857162296772003

00:18:12.071 -> 00:18:14.027 Herceptin would have

NOTE Confidence: 0.857162296772003
00:18:14.027 -> 00:18:16.895 activity in the her 2 positive
NOTE Confidence: 0.857162296772003
00:18:16.895 -> 00:18:19.970 gastric and esophageal adenocarcinomas.
NOTE Confidence: 0.857162296772003
00:18:19.970 -> 00:18:23.260 So there was a large global effort
NOTE Confidence: 0.857162296772003
00:18:23.260 -> 00:18:25.630 to answer that question.
NOTE Confidence: 0.857162296772003
00:18:25.630 -> 00:18:28.670 Patients with advanced disease, metastatic
NOTE Confidence: 0.857162296772003
00:18:28.670 -> 00:18:32.606 or stage four were assigned to get
NOTE Confidence: 0.857162296772003
00:18:32.606 -> 00:18:35.413 the standard of care at that time,
NOTE Confidence: 0.857162296772003
00:18:35.420 -> 00:18:37.504 chemotherapy with two drugs
NOTE Confidence: 0.857162296772003
00:18:37.504 -> 00:18:39.067 or chemotherapy plus
NOTE Confidence: 0.857162296772003
00:18:39.070 -> 00:18:41.385 Herceptin and the results
NOTE Confidence: 0.857162296772003
00:18:41.385 -> 00:18:44.773 of that study were really quite stunning
NOTE Confidence: 0.857162296772003
00:18:44.773 -> 00:18:47.268 in that survival was significantly
NOTE Confidence: 0.857162296772003
00:18:47.268 -> 00:18:49.695 improved for those patients who
NOTE Confidence: 0.857162296772003
00:18:49.695 -> 00:18:52.663 received Herceptin.
NOTE Confidence: 0.857162296772003
00:18:52.670 -> 00:18:55.870 So I would say that was the first
NOTE Confidence: 0.857162296772003

00:18:55.870 -> 00:18:58.722 big advance and changed the paradigm

NOTE Confidence: 0.857162296772003

00:18:58.722 -> 00:19:01.656 about how we think about these

NOTE Confidence: 0.857162296772003

00:19:01.753 -> 00:19:05.239 cancers in terms of looking at the

NOTE Confidence: 0.857162296772003

00:19:05.239 -> 00:19:07.212 molecular profile and thinking

NOTE Confidence: 0.857162296772003

00:19:07.212 -> 00:19:09.100 about using targeted therapies.

NOTE Confidence: 0.857162296772003

00:19:09.100 -> 00:19:12.570 So that was very exciting.

NOTE Confidence: 0.857162296772003

00:19:12.570 -> 00:19:14.225 And then what happened?

NOTE Confidence: 0.857162296772003

00:19:14.225 -> 00:19:16.286 It sounds like there's

NOTE Confidence: 0.857162296772003

00:19:16.286 -> 00:19:18.770 another shoe that's about to drop.

NOTE Confidence: 0.857162296772003

00:19:18.770 -> 00:19:22.066 There is, so in the breast cancer world

NOTE Confidence: 0.857162296772003

00:19:22.070 -> 00:19:24.338 what followed on after the discovery

NOTE Confidence: 0.857162296772003

00:19:24.338 -> 00:19:26.812 of Herceptin was the development of

NOTE Confidence: 0.857162296772003

00:19:26.812 -> 00:19:29.494 other drugs that targeted this protein

NOTE Confidence: 0.857162296772003

00:19:29.500 -> 00:19:31.912 Her 2 and there were additional

NOTE Confidence: 0.857162296772003

00:19:31.912 -> 00:19:34.009 drugs that were developed and

NOTE Confidence: 0.857162296772003

00:19:34.009 -> 00:19:36.109 approved and that were effective.

NOTE Confidence: 0.857162296772003

00:19:36.110 -> 00:19:38.355 But unfortunately when those drugs

NOTE Confidence: 0.857162296772003

00:19:38.355 -> 00:19:40.600 were tested in gastroesophageal

NOTE Confidence: 0.857162296772003

00:19:40.672 -> 00:19:43.248 cancers that were positive for her 2,

NOTE Confidence: 0.857162296772003

00:19:43.250 -> 00:19:46.442 They were not effective and that was

NOTE Confidence: 0.857162296772003

00:19:46.442 -> 00:19:49.434 disappointing and so we were learning

NOTE Confidence: 0.857162296772003

00:19:49.434 -> 00:19:52.506 that her 2 positive gastroesophageal

NOTE Confidence: 0.857162296772003

00:19:52.506 -> 00:19:55.027 cancer is not the same thing as

NOTE Confidence: 0.820176362991333

00:19:55.030 -> 00:19:57.290 her 2 positive breast cancer.

NOTE Confidence: 0.820176362991333

00:19:57.290 -> 00:20:00.008 That's interesting. So wait a second,

NOTE Confidence: 0.820176362991333

00:20:00.010 -> 00:20:02.880 what you're saying is that

NOTE Confidence: 0.820176362991333

00:20:02.880 -> 00:20:05.701 trust Herceptin worked in her

NOTE Confidence: 0.820176362991333

00:20:05.701 -> 00:20:07.709 2 positive gastric cancer,

NOTE Confidence: 0.820176362991333

00:20:07.710 -> 00:20:09.522 but Pertuzumab, I'm assuming

NOTE Confidence: 0.820176362991333

00:20:09.522 -> 00:20:12.240 that you meant pertuzumab,

NOTE Confidence: 0.820176362991333

00:20:12.240 -> 00:20:15.320 which also targets her 2, did not work.

NOTE Confidence: 0.818768918514252

00:20:18.568 -> 00:20:21.457 It did not in the studies that were conducted as well as the antibody

NOTE Confidence: 0.818768918514252

00:20:21.457 -> 00:20:24.568 drug conjugate TDM one and lapatinib.

NOTE Confidence: 0.818768918514252

00:20:26.178 -> 00:20:27.786 Any why was that?

NOTE Confidence: 0.818768918514252

00:20:27.790 -> 00:20:30.614 I mean do they think that

NOTE Confidence: 0.818768918514252

00:20:30.614 -> 00:20:32.686 there was something particular about

NOTE Confidence: 0.818768918514252

00:20:32.686 -> 00:20:36.570 her 2 or was it or about Herceptin

NOTE Confidence: 0.818768918514252

00:20:36.570 -> 00:20:39.440 versus the other drugs in terms

NOTE Confidence: 0.818768918514252

00:20:39.440 -> 00:20:42.256 of what particular subunit of her 2

NOTE Confidence: 0.818768918514252

00:20:42.260 -> 00:20:43.490 that we're targeting?

NOTE Confidence: 0.818768918514252

00:20:43.490 -> 00:20:45.950 Or what was the

NOTE Confidence: 0.818768918514252

00:20:45.950 -> 00:20:47.615 hypothesis behind why

NOTE Confidence: 0.818768918514252

00:20:47.615 -> 00:20:50.950 one drug would work, but the

NOTE Confidence: 0.869497895240784

00:20:50.950 -> 00:20:51.754 others didn't?

NOTE Confidence: 0.869497895240784

00:20:51.754 -> 00:20:54.970 That is a great question and I don't

NOTE Confidence: 0.869497895240784

00:20:55.056 -> 00:20:57.737 know that we have all the answers.

NOTE Confidence: 0.869497895240784

00:20:57.740 -> 00:21:00.170 We do know that gastroesophageal cancers

NOTE Confidence: 0.869497895240784

00:21:00.170 -> 00:21:02.501 are much more heterogeneous in terms

NOTE Confidence: 0.869497895240784

00:21:02.501 -> 00:21:04.433 of their levels of expression are

NOTE Confidence: 0.869497895240784

00:21:04.433 -> 00:21:06.807 more likely to lose expression overtime,

NOTE Confidence: 0.869497895240784

00:21:06.810 -> 00:21:08.086 so that's one issue.

NOTE Confidence: 0.869497895240784

00:21:08.086 -> 00:21:11.382 Some of it may have been related to how

NOTE Confidence: 0.869497895240784

00:21:11.382 -> 00:21:13.986 the studies were designed and conducted,

NOTE Confidence: 0.869497895240784

00:21:13.990 -> 00:21:16.524 but I don't think we fully understand

NOTE Confidence: 0.869497895240784

00:21:16.524 -> 00:21:19.529 why we don't see the exact same activity

NOTE Confidence: 0.869497895240784

00:21:19.529 -> 00:21:22.319 of some of these agents in gastric

NOTE Confidence: 0.869497895240784

00:21:22.320 -> 00:21:24.405 and esophageal adenocarcinomas that we're

NOTE Confidence: 0.869497895240784

00:21:24.405 -> 00:21:26.910 seeing in breast cancer.

NOTE Confidence: 0.85562664270401

00:21:26.910 -> 00:21:29.346 Sorry to interrupt, but it still

NOTE Confidence: 0.85562664270401

00:21:29.346 -> 00:21:32.328 sounds like there was another shoe that

NOTE Confidence: 0.85562664270401

00:21:32.330 -> 00:21:33.994 was going to drop.

NOTE Confidence: 0.85562664270401

00:21:33.994 -> 00:21:36.780 Well, I think we're very excited in

NOTE Confidence: 0.85562664270401

00:21:36.780 -> 00:21:39.654 that it does appear that there is

NOTE Confidence: 0.85562664270401

00:21:39.654 -> 00:21:42.475 going to be newer generations of her

NOTE Confidence: 0.85562664270401

00:21:42.562 -> 00:21:45.172 2 targeting agents that are going

NOTE Confidence: 0.85562664270401

00:21:45.172 -> 00:21:47.778 to be effective in gastric cancer.

NOTE Confidence: 0.85562664270401

00:21:47.778 -> 00:21:50.781 So one of them is a very

NOTE Confidence: 0.85562664270401

00:21:50.781 -> 00:21:52.368 interesting drug that is

NOTE Confidence: 0.85562664270401

00:21:52.370 -> 00:21:55.946 also used in breast cancer now very recently

NOTE Confidence: 0.85562664270401

00:21:55.946 -> 00:21:58.998 where you take Herceptin and you

NOTE Confidence: 0.85562664270401

00:21:59.000 -> 00:22:01.394 link it up biochemically to a

NOTE Confidence: 0.85562664270401

00:22:01.394 -> 00:22:02.990 chemotherapeutic drug.

NOTE Confidence: 0.85562664270401

00:22:09.073 -> 00:22:13.137 And that has been approved in breast cancer.

NOTE Confidence: 0.85562664270401

00:22:13.140 -> 00:22:15.625 That's her 2 positive and has been

NOTE Confidence: 0.85562664270401

00:22:15.625 -> 00:22:18.767 tested now and her 2 positive gastroesophageal

NOTE Confidence: 0.85562664270401

00:22:18.767 -> 00:22:20.771 adenocarcinomas in patients

NOTE Confidence: 0.85562664270401

00:22:20.771 -> 00:22:23.797 who have already been on trastuzumab

NOTE Confidence: 0.85562664270401

00:22:23.800 -> 00:22:25.954 and have failed treatment and the

NOTE Confidence: 0.85562664270401

00:22:25.954 -> 00:22:27.390 results really were stunning.

NOTE Confidence: 0.85562664270401

00:22:27.390 -> 00:22:29.185 With major shrinkage in more

NOTE Confidence: 0.85562664270401

00:22:29.185 -> 00:22:30.980 than half of the patients,

NOTE Confidence: 0.85562664270401

00:22:30.980 -> 00:22:32.996 which is not something that we

NOTE Confidence: 0.85562664270401

00:22:32.996 -> 00:22:34.930 typically see in this disease.

NOTE Confidence: 0.85562664270401

00:22:34.930 -> 00:22:37.084 Really with any line of therapy

NOTE Confidence: 0.85562664270401

00:22:37.084 -> 00:22:38.520 and very impressive survival.

NOTE Confidence: 0.85562664270401

00:22:38.520 -> 00:22:40.310 So this is very exciting.

NOTE Confidence: 0.85562664270401

00:22:40.310 -> 00:22:42.476 There was a New England Journal

NOTE Confidence: 0.85562664270401

00:22:42.476 -> 00:22:44.328 of Medicine paper regarding this

NOTE Confidence: 0.85562664270401

00:22:44.328 -> 00:22:45.700 data earlier this year,

NOTE Confidence: 0.85562664270401

00:22:45.700 -> 00:22:47.490 and I do believe this

NOTE Confidence: 0.85562664270401

00:22:47.490 -> 00:22:49.709 new drug will be approved not

NOTE Confidence: 0.85562664270401

00:22:49.709 -> 00:22:52.736 only in breast cancer but also in her

NOTE Confidence: 0.85562664270401

00:22:52.736 -> 00:22:54.741 2 positive gastroesophageal cancer.

NOTE Confidence: 0.85562664270401

00:22:54.750 -> 00:22:57.696 So we're very excited about that.

NOTE Confidence: 0.85562664270401

00:22:57.700 -> 00:22:58.598 And again,

NOTE Confidence: 0.85562664270401

00:22:58.598 -> 00:23:01.741 this is for our patients who

NOTE Confidence: 0.85562664270401

00:23:01.741 -> 00:23:05.058 have her two positive tumors.

NOTE Confidence: 0.85562664270401

00:23:05.060 -> 00:23:08.006 So it's not for all comers.

NOTE Confidence: 0.85562664270401

00:23:08.010 -> 00:23:09.698 So that's one development.

NOTE Confidence: 0.85562664270401

00:23:09.698 -> 00:23:13.321 And then I think we will also see

NOTE Confidence: 0.85562664270401

00:23:13.321 -> 00:23:15.337 some newer generation antibodies

NOTE Confidence: 0.85562664270401

00:23:15.337 -> 00:23:18.502 that are similar to trastuzumab but

NOTE Confidence: 0.85562664270401

00:23:18.502 -> 00:23:21.676 more potent in recruiting the immune

NOTE Confidence: 0.85562664270401

00:23:21.676 -> 00:23:25.200 system into action to kill the cancer.

NOTE Confidence: 0.85562664270401

00:23:25.200 -> 00:23:29.384 And so one of those is called margetuximab,

NOTE Confidence: 0.85562664270401

00:23:29.390 -> 00:23:32.010 so quite similar to trastuzumab,

NOTE Confidence: 0.85562664270401

00:23:32.010 -> 00:23:34.614 but it enhances the immune response

NOTE Confidence: 0.85562664270401

00:23:34.614 -> 00:23:37.549 and we've already seen really positive

NOTE Confidence: 0.85562664270401

00:23:37.549 -> 00:23:40.354 and exciting preliminary data when
NOTE Confidence: 0.85562664270401

00:23:40.354 -> 00:23:43.539 it is combined with immunotherapy.
NOTE Confidence: 0.85562664270401

00:23:43.540 -> 00:23:46.684 And there's a very exciting on
NOTE Confidence: 0.85562664270401

00:23:46.684 -> 00:23:48.256 going clinical trial
NOTE Confidence: 0.85562664270401

00:23:48.260 -> 00:23:50.930 looking at this combination of
NOTE Confidence: 0.85562664270401

00:23:50.930 -> 00:23:53.066 margetuximab in immunotherapy with
NOTE Confidence: 0.85562664270401

00:23:53.066 -> 00:23:55.588 chemotherapy in newly diagnosed patients.
NOTE Confidence: 0.85562664270401

00:23:55.590 -> 00:23:57.458 So we're very excited
NOTE Confidence: 0.85562664270401

00:23:57.458 -> 00:24:00.260 about the second and third generation
NOTE Confidence: 0.85562664270401

00:24:00.344 -> 00:24:02.756 iterations
NOTE Confidence: 0.85562664270401

00:24:02.760 -> 00:24:05.581 and then there are other novel antibodies
NOTE Confidence: 0.85562664270401

00:24:05.581 -> 00:24:08.569 targeting her 2 that are being developed,
NOTE Confidence: 0.85562664270401

00:24:08.570 -> 00:24:11.242 so I do think that the field is
NOTE Confidence: 0.85562664270401

00:24:11.242 -> 00:24:13.945 really going to open up in terms of
NOTE Confidence: 0.85562664270401

00:24:13.945 -> 00:24:16.675 treatment of her 2 positive stage
NOTE Confidence: 0.85562664270401

00:24:16.675 -> 00:24:19.359 for gastroesophageal adenocarcinoma.

00:24:19.725 -> 00:24:21.915 I'm very hopeful that the prognosis
NOTE Confidence: 0.85562664270401

00:24:21.915 -> 00:24:24.050 for these patients will improve
NOTE Confidence: 0.85562664270401

00:24:24.050 -> 00:24:25.998 significantly with these therapies.
NOTE Confidence: 0.854938805103302

00:24:26.000 -> 00:24:28.954 But there's still a large fraction of
NOTE Confidence: 0.854938805103302

00:24:28.960 -> 00:24:31.996 patients who are her 2 negative,
NOTE Confidence: 0.854938805103302

00:24:32.000 -> 00:24:34.020 So what about them?
NOTE Confidence: 0.854938805103302

00:24:34.020 -> 00:24:35.535 Does standard immunotherapy,
NOTE Confidence: 0.854938805103302

00:24:35.540 -> 00:24:38.070 for example with checkpoint inhibitors,
NOTE Confidence: 0.829631650447846

00:24:38.070 -> 00:24:41.000 help them?
NOTE Confidence: 0.829631650447846

00:24:41.000 -> 00:24:44.255 This is where there's some excitement really
NOTE Confidence: 0.829631650447846

00:24:44.260 -> 00:24:47.056 just in the past few months.
NOTE Confidence: 0.829631650447846

00:24:47.060 -> 00:24:49.850 So we hear a lot about
NOTE Confidence: 0.829631650447846

00:24:49.850 -> 00:24:51.245 immune checkpoint inhibitors.
NOTE Confidence: 0.829631650447846

00:24:51.250 -> 00:24:54.512 Drugs like KEYTRUDA
NOTE Confidence: 0.829631650447846

00:24:54.512 -> 00:24:57.309 or Opdivo in colon cancer,
NOTE Confidence: 0.829631650447846

00:24:57.310 -> 00:24:58.780 lung cancer, Melanoma,

NOTE Confidence: 0.829631650447846
00:24:58.780 -> 00:25:01.230 and many other cancers where
NOTE Confidence: 0.829631650447846
00:25:01.230 -> 00:25:02.690 these immunotherapeutic agents
NOTE Confidence: 0.829631650447846
00:25:02.690 -> 00:25:04.755 have really been game changers.
NOTE Confidence: 0.829631650447846
00:25:04.760 -> 00:25:08.141 These agents in the way the studies
NOTE Confidence: 0.829631650447846
00:25:08.141 -> 00:25:11.327 have been done to date have not
NOTE Confidence: 0.829631650447846
00:25:11.330 -> 00:25:14.420 appeared to have a significant
NOTE Confidence: 0.829631650447846
00:25:14.420 -> 00:25:17.510 impact in gastroesophageal cancer.
NOTE Confidence: 0.829631650447846
00:25:17.510 -> 00:25:20.884 But there is some activity and we're
NOTE Confidence: 0.829631650447846
00:25:20.884 -> 00:25:23.374 learning more about who should
NOTE Confidence: 0.829631650447846
00:25:23.374 -> 00:25:26.218 get these agents who will benefit
NOTE Confidence: 0.829631650447846
00:25:26.218 -> 00:25:29.009 most when and how to use them.
NOTE Confidence: 0.829631650447846
00:25:29.010 -> 00:25:32.786 And I think that's where the field is
NOTE Confidence: 0.829631650447846
00:25:32.786 -> 00:25:35.907 moving forward in a very positive way.
NOTE Confidence: 0.829631650447846
00:25:35.910 -> 00:25:38.658 So there are already FDA approvals
NOTE Confidence: 0.829631650447846
00:25:41.430 -> 00:25:43.270 for classical immune checkpoint inhibitors,
NOTE Confidence: 0.829631650447846

00:25:43.270 -> 00:25:44.650 and gastroesophageal cancer,
NOTE Confidence: 0.829631650447846

00:25:44.650 -> 00:25:47.352 so we can use KEYTRUDA
NOTE Confidence: 0.829631650447846

00:25:47.352 -> 00:25:49.799 in patients who failed standard
NOTE Confidence: 0.829631650447846

00:25:49.799 -> 00:25:52.799 several lines of standard therapy
NOTE Confidence: 0.829631650447846

00:25:52.800 -> 00:25:56.349 if their tumor expresses the target PDL1
NOTE Confidence: 0.829631650447846

00:25:56.870 -> 00:25:59.470 that's for gastric and gastroesophageal
NOTE Confidence: 0.829631650447846

00:25:59.470 -> 00:26:01.550 adenocarcinomas and it
NOTE Confidence: 0.829631650447846

00:26:01.624 -> 00:26:04.258 is also approved in esophageal
NOTE Confidence: 0.829631650447846

00:26:04.258 -> 00:26:06.014 squamous cell carcinoma after
NOTE Confidence: 0.829631650447846

00:26:06.086 -> 00:26:08.518 standard initial chemotherapy works.
NOTE Confidence: 0.829631650447846

00:26:08.520 -> 00:26:11.817 And the results are very
NOTE Confidence: 0.829631650447846

00:26:11.817 -> 00:26:14.577 impressive there and it's also active
NOTE Confidence: 0.829631650447846

00:26:14.577 -> 00:26:17.524 in a very small subset of patients
NOTE Confidence: 0.829631650447846

00:26:17.613 -> 00:26:21.279 whose tumors are characterized by what
NOTE Confidence: 0.829631650447846

00:26:21.279 -> 00:26:23.723 we call microsatellite instability.
NOTE Confidence: 0.829631650447846

00:26:23.730 -> 00:26:26.796 Or loss of a DNA repair mechanism.

NOTE Confidence: 0.829631650447846
00:26:26.800 -> 00:26:29.290 These tumors are characterized by lots
NOTE Confidence: 0.829631650447846
00:26:29.290 -> 00:26:31.610 of mutations in abnormal proteins.
NOTE Confidence: 0.829631650447846
00:26:31.610 -> 00:26:34.238 And respond very well to
NOTE Confidence: 0.829631650447846
00:26:34.238 -> 00:26:35.552 checkpoint inhibitors,
NOTE Confidence: 0.829631650447846
00:26:35.560 -> 00:26:38.843 but that's a small percentage in the
NOTE Confidence: 0.829631650447846
00:26:38.843 -> 00:26:41.702 range of three to 5%.
NOTE Confidence: 0.829631650447846
00:26:41.702 -> 00:26:44.824 So what's most exciting is data that
NOTE Confidence: 0.829631650447846
00:26:44.824 -> 00:26:48.294 we heard really just a few months ago
NOTE Confidence: 0.829631650447846
00:26:48.300 -> 00:26:50.492 regarding the incorporation of
NOTE Confidence: 0.829631650447846
00:26:50.492 -> 00:26:52.684 immune checkpoint inhibitors into
NOTE Confidence: 0.829631650447846
00:26:52.684 -> 00:26:55.590 the initial treatment of stage four,
NOTE Confidence: 0.829631650447846
00:26:55.590 -> 00:26:57.156 gastric and esophageal cancers.
NOTE Confidence: 0.829631650447846
00:26:58.200 -> 00:27:01.497 And so there were a couple of
NOTE Confidence: 0.829631650447846
00:27:01.497 -> 00:27:04.185 studies that were presented at
NOTE Confidence: 0.829631650447846
00:27:04.185 -> 00:27:07.120 the major meeting in Europe.
NOTE Confidence: 0.829631650447846

00:27:07.120 -> 00:27:08.948 Both had similar designs.
NOTE Confidence: 0.829631650447846

00:27:08.948 -> 00:27:11.690 One was focused on gastroesophageal
NOTE Confidence: 0.829631650447846

00:27:11.768 -> 00:27:14.053 adenocarcinoma and in this study
NOTE Confidence: 0.829631650447846

00:27:14.053 -> 00:27:16.338 patients were given either the
NOTE Confidence: 0.829631650447846

00:27:16.416 -> 00:27:18.740 standard two drug chemotherapy,
NOTE Confidence: 0.829631650447846

00:27:18.740 -> 00:27:21.350 standard of care, or those same
NOTE Confidence: 0.829631650447846

00:27:21.350 -> 00:27:23.632 two chemotherapy drugs with no
NOTE Confidence: 0.829631650447846

00:27:23.632 -> 00:27:25.922 OPDIVO and again
NOTE Confidence: 0.829631650447846

00:27:25.922 -> 00:27:28.435 really exciting results with the
NOTE Confidence: 0.829631650447846

00:27:28.435 -> 00:27:30.839 significant improvement in survival.
NOTE Confidence: 0.829631650447846

00:27:30.840 -> 00:27:33.255 A higher response rate and
NOTE Confidence: 0.829631650447846

00:27:33.255 -> 00:27:34.704 excellent tolerability.
NOTE Confidence: 0.829631650447846

00:27:34.710 -> 00:27:37.626 So lots of excitement about that.
NOTE Confidence: 0.829631650447846

00:27:37.630 -> 00:27:41.582 And then a second study with a very
NOTE Confidence: 0.829631650447846

00:27:41.582 -> 00:27:44.458 similar design of chemo or chemo,
NOTE Confidence: 0.829631650447846

00:27:44.460 -> 00:27:47.876 with in this case KEYTRUDA

NOTE Confidence: 0.829631650447846

00:27:47.880 -> 00:27:52.263 and here the focus was an again on esophageal cancer,

NOTE Confidence: 0.829631650447846

00:27:52.270 -> 00:27:54.126 both squamous and adenocarcinoma,

NOTE Confidence: 0.829631650447846

00:27:54.126 -> 00:27:57.499 and again a similar exciting result showing

NOTE Confidence: 0.829631650447846

00:27:57.499 -> 00:28:00.079 a significant improvement in survival.

NOTE Confidence: 0.829631650447846

00:28:00.080 -> 00:28:03.976 Actually a doubling of survival at two years.

NOTE Confidence: 0.829631650447846

00:28:03.980 -> 00:28:07.924 So this is really great news

00:28:08.406 -> 00:28:10.786 for patients with these diseases,

NOTE Confidence: 0.829631650447846

00:28:10.790 -> 00:28:13.919 and I do think that these studies

NOTE Confidence: 0.829631650447846

00:28:13.919 -> 00:28:16.373 will ultimately lead to new

NOTE Confidence: 0.829631650447846

00:28:16.373 -> 00:28:18.417 indications and FDA approvals.

NOTE Confidence: 0.829631650447846

00:28:18.420 -> 00:28:20.328 We're not there yet,

NOTE Confidence: 0.829631650447846

00:28:20.328 -> 00:28:22.236 but I think we're

NOTE Confidence: 0.837908208370209

00:28:22.240 -> 00:28:24.625 getting close.

NOTE Confidence: 0.837908208370209

00:28:24.625 -> 00:28:27.010 What about in terms of other targeted therapies?

NOTE Confidence: 0.837908208370209

00:28:27.010 -> 00:28:29.810 You know we have talked on this

NOTE Confidence: 0.837908208370209

00:28:29.810 -> 00:28:32.656 show with other people from other
NOTE Confidence: 0.837908208370209

00:28:32.656 -> 00:28:35.251 disease groups and other cancer
NOTE Confidence: 0.837908208370209

00:28:35.251 -> 00:28:37.998 types about looking at cancers
NOTE Confidence: 0.837908208370209

00:28:38.000 -> 00:28:40.860 and seeing what genes are turned on
NOTE Confidence: 0.837908208370209

00:28:40.860 -> 00:28:44.116 and turned off to try to target these?
NOTE Confidence: 0.837908208370209

00:28:44.120 -> 00:28:46.969 How much of that goes on in
NOTE Confidence: 0.837908208370209

00:28:46.969 -> 00:28:47.783 gastroesophageal cancers?
NOTE Confidence: 0.837908208370209

00:28:47.790 -> 00:28:50.450 Are we getting there in terms of
NOTE Confidence: 0.837908208370209

00:28:50.450 -> 00:28:52.690 genomic analysis of these cancers
NOTE Confidence: 0.837908208370209

00:28:52.690 -> 00:28:55.138 and being able to target them
NOTE Confidence: 0.837908208370209

00:28:55.138 -> 00:28:56.770 aside from her 2?
NOTE Confidence: 0.854126632213593

00:28:57.540 -> 00:29:00.140 Yes, absolutely, so we routinely
NOTE Confidence: 0.854126632213593

00:29:00.140 -> 00:29:03.510 recommend that all patients with advanced
NOTE Confidence: 0.854126632213593

00:29:03.510 -> 00:29:05.553 gastroesophageal adenocarcinomas
NOTE Confidence: 0.854126632213593

00:29:05.553 -> 00:29:08.958 and squamous cell carcinomas
NOTE Confidence: 0.854126632213593

00:29:08.958 -> 00:29:12.649 undergo what is referred to as tumor

NOTE Confidence: 0.854126632213593
00:29:12.649 -> 00:29:15.746 profiling or molecular profiling to look
NOTE Confidence: 0.854126632213593
00:29:15.746 -> 00:29:19.722 at the genetic makeup of the tumor
NOTE Confidence: 0.854126632213593
00:29:19.730 -> 00:29:23.150 to see what makes it tick.
NOTE Confidence: 0.854126632213593
00:29:23.150 -> 00:29:26.948 Now we haven't identified a high
NOTE Confidence: 0.854126632213593
00:29:26.948 -> 00:29:29.480 frequency of recurring targets.
NOTE Confidence: 0.854126632213593
00:29:29.480 -> 00:29:31.958 To date, other than her 2,
NOTE Confidence: 0.854126632213593
00:29:31.960 -> 00:29:34.810 but there are targets that are
NOTE Confidence: 0.854126632213593
00:29:34.810 -> 00:29:36.710 expressed with reasonable frequency
NOTE Confidence: 0.854126632213593
00:29:36.786 -> 00:29:39.509 that are what we call actionable or
NOTE Confidence: 0.854126632213593
00:29:39.509 -> 00:29:41.828 druggable where we can develop a
NOTE Confidence: 0.854126632213593
00:29:41.828 -> 00:29:44.348 drug or have a drug that potentially
NOTE Confidence: 0.854126632213593
00:29:44.350 -> 00:29:46.034 could target that abnormality.
NOTE Confidence: 0.854126632213593
00:29:46.034 -> 00:29:48.560 So we've talked at length today
NOTE Confidence: 0.854126632213593
00:29:48.634 -> 00:29:50.130 already about her 2,
NOTE Confidence: 0.854126632213593
00:29:50.130 -> 00:29:52.788 and that's a critically important
NOTE Confidence: 0.854126632213593

00:29:52.788 -> 00:29:55.501 target in those 25 to 30% patients
NOTE Confidence: 0.854126632213593

00:29:55.501 -> 00:29:57.556 and again another exciting development
NOTE Confidence: 0.854126632213593

00:30:00.930 -> 00:30:03.026 that I think we are on the cusp of is another targeted therapy.
NOTE Confidence: 0.854126632213593

00:30:03.026 -> 00:30:05.646 This again is an antibody
00:30:08.038 -> 00:30:10.364 that is targeting another
NOTE Confidence: 0.854126632213593

00:30:10.364 -> 00:30:12.980 protein called fibroblast growth
NOTE Confidence: 0.854126632213593

00:30:12.980 -> 00:30:15.596 factor receptor and
NOTE Confidence: 0.854126632213593

00:30:15.600 -> 00:30:17.211 like her 2,
NOTE Confidence: 0.854126632213593

00:30:17.211 -> 00:30:20.433 is expressed on the surface and
NOTE Confidence: 0.854126632213593

00:30:20.433 -> 00:30:24.552 again in about probably 20 to 30% of
NOTE Confidence: 0.854126632213593

00:30:24.552 -> 00:30:27.924 patients is expressed at very high
NOTE Confidence: 0.854126632213593

00:30:27.924 -> 00:30:31.339 levels or overexpressed and this has been
NOTE Confidence: 0.854126632213593

00:30:31.340 -> 00:30:34.996 a target for the development of an antibody,
NOTE Confidence: 0.854126632213593

00:30:35.000 -> 00:30:37.526 and we heard really just this
NOTE Confidence: 0.854126632213593

00:30:37.526 -> 00:30:40.020 week from a press release,
NOTE Confidence: 0.854126632213593

00:30:40.020 -> 00:30:42.768 so we haven't seen the data,

NOTE Confidence: 0.854126632213593
00:30:42.770 -> 00:30:45.930 so we have to stay tuned, that a
NOTE Confidence: 0.854126632213593
00:30:45.930 -> 00:30:48.569 study looking at patients who have
NOTE Confidence: 0.854126632213593
00:30:48.569 -> 00:30:51.813 this target looking at
NOTE Confidence: 0.854126632213593
00:30:51.813 -> 00:30:54.403 these patients and combining the
NOTE Confidence: 0.854126632213593
00:30:54.403 -> 00:30:57.342 antibody that targets FG FR2 with
NOTE Confidence: 0.854126632213593
00:30:57.342 -> 00:30:59.497 chemotherapy and comparing that to
NOTE Confidence: 0.854126632213593
00:30:59.497 -> 00:31:02.230 standard of care chemotherapy alone.
NOTE Confidence: 0.854126632213593
00:31:02.230 -> 00:31:05.278 And at least based on the press release,
NOTE Confidence: 0.854126632213593
00:31:05.280 -> 00:31:08.709 this looks like it will be a positive study.
NOTE Confidence: 0.854126632213593
00:31:08.710 -> 00:31:09.450 So again,
NOTE Confidence: 0.854126632213593
00:31:09.450 -> 00:31:11.670 quite a bit of excitement and
NOTE Confidence: 0.854126632213593
00:31:11.670 -> 00:31:13.280 buzz in the field.
00:31:21.660 -> 00:31:23.160 So there's one example,
NOTE Confidence: 0.854126632213593
00:31:23.160 -> 00:31:25.862 there are several others and drugs in
NOTE Confidence: 0.854126632213593
00:31:25.862 -> 00:31:28.136 the pipeline looking at other targets.
NOTE Confidence: 0.854126632213593
00:31:28.140 -> 00:31:28.520 Doctor Jill Lacy

NOTE Confidence: 0.867128193378448
00:31:28.520 -> 00:31:30.932 is a professor of
NOTE Confidence: 0.867128193378448
00:31:30.932 -> 00:31:32.540 medicine and medical oncology
NOTE Confidence: 0.867128193378448
00:31:32.617 -> 00:31:34.765 at the Yale School of Medicine.
NOTE Confidence: 0.867128193378448
00:31:34.770 -> 00:31:36.330 If you have questions,
NOTE Confidence: 0.867128193378448
00:31:36.330 -> 00:31:37.890 the address is canceranswers@yale.edu
NOTE Confidence: 0.867128193378448
00:31:37.890 -> 00:31:40.047 and past editions of the program
NOTE Confidence: 0.867128193378448
00:31:40.047 -> 00:31:42.015 are available in audio and written
NOTE Confidence: 0.867128193378448
00:31:42.077 -> 00:31:43.718 form at yalecancercenter.org.
NOTE Confidence: 0.867128193378448
00:31:43.720 -> 00:31:46.328 We hope you'll join us next week to
NOTE Confidence: 0.867128193378448
00:31:46.328 -> 00:31:48.860 learn more about the fight against
NOTE Confidence: 0.867128193378448
00:31:48.860 -> 00:31:51.504 cancer here on Connecticut Public Radio.